In This Article:
As global markets navigate a period of heightened economic activity and mixed signals from earnings reports, investors are keenly observing the performance of major indices, which have seen fluctuations amid busy data weeks. With value stocks showing resilience compared to their growth counterparts, this environment presents an opportunity to identify stocks that may be trading below their intrinsic worth. In such a climate, finding undervalued stocks requires a focus on strong fundamentals and potential for recovery or growth despite broader market volatility.
Top 10 Undervalued Stocks Based On Cash Flows
Name | Current Price | Fair Value (Est) | Discount (Est) |
Provident Financial Services (NYSE:PFS) | US$18.85 | US$37.47 | 49.7% |
Proya CosmeticsLtd (SHSE:603605) | CN¥97.24 | CN¥194.47 | 50% |
Arteche Lantegi Elkartea (BME:ART) | €6.10 | €12.20 | 50% |
Elica (BIT:ELC) | €1.725 | €3.44 | 49.8% |
Beyout Investment Group Holding Company - K.S.C. (Holding) (KWSE:BEYOUT) | KWD0.395 | KWD0.79 | 50% |
Bangkok Genomics Innovation (SET:BKGI) | THB2.68 | THB5.35 | 49.9% |
BayCurrent Consulting (TSE:6532) | ¥4902.00 | ¥9762.93 | 49.8% |
Redcentric (AIM:RCN) | £1.20 | £2.39 | 49.8% |
Beijing LeiKe Defense Technology (SZSE:002413) | CN¥4.72 | CN¥9.39 | 49.8% |
Alnylam Pharmaceuticals (NasdaqGS:ALNY) | US$273.91 | US$546.14 | 49.8% |
Below we spotlight a couple of our favorites from our exclusive screener.
argenx
Overview: argenx SE is a biotechnology company focused on developing therapies for autoimmune diseases across the United States, Japan, Europe, the Middle East, Africa, and China with a market cap of €32.98 billion.
Operations: The company generates revenue from its biotechnology segment, amounting to $1.91 billion.
Estimated Discount To Fair Value: 44.8%
argenx is trading significantly below its estimated fair value, with a valuation gap exceeding 20% based on discounted cash flow analysis. Recent FDA approval of VYVGART Hytrulo for CIDP and strong clinical trial results bolster its growth prospects. Despite notable insider selling, revenue is forecast to grow at 26.2% annually, outpacing the Belgian market's average, and earnings are expected to increase by 58.04% per year as profitability approaches within three years.
-
According our earnings growth report, there's an indication that argenx might be ready to expand.
-
Navigate through the intricacies of argenx with our comprehensive financial health report here.
GFL Environmental
Overview: GFL Environmental Inc. provides non-hazardous solid waste management and environmental services in Canada and the United States, with a market cap of CA$22.84 billion.